In conclusion, we demonstrated that TACE-activity inhibition by Marimastat in two murine models of hepatic steatosis resulted in reversal of steatosis, coupled with improvement of surrogate markers of insulin sensitivity. Here, ADAM17 is linked to fatty liver disease.